The EPS beat is small for a pre-revenue biotech — the stock will trade on pipeline catalysts. Watch the ASGCT oral presentation on May 15 for updated efficacy/safety data on high-dose BB-301. FDA engagement mid-year could de-risk pivotal trial design. The $184.8M cash position removes near-term financing risk.
Price Chart
Executive Summary
Benitec Biopharma reported Q3 FY2026 (March 31, 2026) net loss of $0.24/share, beating consensus of -$0.28 by 5.5%. The company highlighted durable clinical responses for BB-301 in OPMD at 12-24 months, safe enrollment of high-dose Cohort 2 patients, and a strong cash position of $184.8M to fund through a pivotal study. The EPS beat is modest and the company remains pre-revenue, so the stock move will depend on pipeline catalysts (ASGCT presentation May 15, FDA engagement mid-year, updated data 2H-2026) rather than the financial results themselves.
Key Financial Metrics
Key Facts
- Net loss of $11.9M ($0.24/share) vs consensus -$0.28 — 5.5% beat
- Cash and equivalents $184.8M as of March 31, 2026, up from $97.7M at June 30, 2025
- BB-301 Phase 1b/2a: durable responses at 12-24 months for low dose; high-dose Cohort 2 patients safely treated with deep efficacy signals
- No treatment-related severe adverse events observed
- Interim results selected for oral presentation at ASGCT on May 15, 2026
- FDA engagement for pivotal study design expected mid-2026; updated interim data in 2H-2026
- Total operating expenses $13.6M, down from $15.3M YoY; R&D expenses flat at $6.3M
Financial Impact
EPS beat of $0.04 vs consensus; cash runway extended to ~3.5 years at current burn rate; no revenue
Risk Factors
- Clinical trial failure or safety signal in high-dose Cohort 2
- FDA may require additional studies or reject pivotal trial design
- Competing therapies for OPMD could emerge
- Stock is pre-revenue with no near-term commercialization path
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294843 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | DEFA14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 20, 2026 6d ago | DEF 14A | $8.50 $8.82 | ▲ +3.76% | ▲ +4.95% | $8.59 (+1.06%) |
Oct 5, 2026 21d ago | 8-K | $9.23 $9.00 | ▼ −2.49% | ▼ −3.04% | $8.59 (−6.93%) |
Sep 30, 2026 26d ago | 8-K | $9.58 $8.98 | ▼ −6.26% | ▼ −7.00% | $8.59 (−10.33%) |
Sep 22, 2026 4w ago | EFFECT | $10.95 $9.83 | ▲ +10.23% | ▲ +9.51% | $8.59 (+21.55%) |
Sep 14, 2026 6w ago | Press Release | $11.05 $11.04 | ▼ −0.09% | ▲ +0.35% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
Jun 11, 2026 19w ago | Institutional Cluster | $11.05 $11.18 | ▲ +1.18% | ▲ +0.64% | $8.59 (−22.26%) |
May 14, 2026 23w ago | 8-K | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
May 14, 2026 23w ago | Press Release | $11.85 $11.49 | ▼ −3.04% | ▼ −1.81% | $8.59 (−27.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers